Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Nexsen Limited ( (AU:NXN) ) has provided an update.
Nexsen Limited will participate as a sponsor, presenter and exhibitor at the International Symposium on Streptococcus agalactiae Disease 2026 in Nairobi, underscoring its strategic focus on Group B Streptococcus diagnostics. Chief Innovation Officer Distinguished Professor Vipul Bansal will present on StrepSure, a point-of-care lateral flow device for rapid intrapartum GBS testing, while the company showcases clinically evaluated units at its exhibition booth.
Managing Director Mark Muzzin will attend to support high-level discussions with global health institutions, industry participants and potential partners, positioning Nexsen alongside major organisations such as the Bill & Melinda Gates Foundation and Pfizer. Nexsen aims to leverage ISSAD 2026 to build international awareness, pursue collaborations and highlight its diagnostic-led approach to improving intrapartum decision-making and antimicrobial stewardship at a time when few rapid, regulatory-cleared point-of-care GBS tests are available in key markets.
Timely identification of maternal GBS colonisation at delivery remains a significant clinical challenge, with current practice often relying on earlier laboratory or antenatal screening that may not reflect status at birth. StrepSure is still under clinical evaluation and not yet approved for commercial use, but Nexsen’s engagement at this global forum may strengthen its industry positioning and stakeholder relationships as it advances the technology toward potential regulatory pathways and commercialisation.
More about Nexsen Limited
Nexsen Limited is an ASX-listed medical diagnostics company focused on point-of-care technologies for infectious disease, with a particular emphasis on Group B Streptococcus in maternal and neonatal health. Its primary product under development is StrepSure, a rapid lateral flow device designed for intrapartum diagnosis of GBS colonisation in expectant mothers, targeting unmet needs in major international markets.
Average Trading Volume: 254,712
See more insights into NXN stock on TipRanks’ Stock Analysis page.